A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience

QJM: An International Journal of Medicine

Volumn 109, Issue 1, 2016, Pages 27-33

  Sheerin, N S ^a,c   Kavanagh, D ^b,c   Goodship, T H J ^b,c   Johnson, S ^c  

^a Institute of Cellular Medicine   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ECULIZUMAB; MONOCLONAL ANTIBODY;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CEREBELLUM HYPOPLASIA; CHILD; CLINICAL ARTICLE; DIALYSIS; DRUG DOSE INCREASE; DRUG WITHDRAWAL; ENGLAND; FEMALE; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERKALEMIA; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAINTENANCE DRUG DOSE; MALE; MIGRAINE; NATIONAL HEALTH SERVICE; PONTO CEREBELLAR HYPOPLASIA TYPE I; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; RETREATMENT; TREATMENT OUTCOME; ADOLESCENT; ATYPICAL HEMOLYTIC UREMIC SYNDROME; HEMODIALYSIS; KIDNEY; MENINGOCOCCAL INFECTIONS; MIDDLE AGED; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; CHILD; CHILD, PRESCHOOL; ENGLAND; FEMALE; HUMANS; KIDNEY; MALE; MENINGOCOCCAL INFECTIONS; MIDDLE AGED; RENAL DIALYSIS; YOUNG ADULT;

EID: 84964480157     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcv082     Document Type: Article

References (15)

1. Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol 2013; 33:508-30.
2. LemaireM, Fremeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 2013; 45:531-6.
3. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5:1844-59.
4. Noris M, Remuzzi G. Thrombotic microangiopathy after kidney transplantation. Am J Transplant 2010; 10:1517-23.
5. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368:2169-81.
6. Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4 and with mutations in CFH, CFI, CD46, and C3 in patients with atypical haemolytic uraemic syndrome. Blood 2010; 115:379-87.
7. Watson R, Lindner S, Bordereau P, Hunze EM, Tak F, Ngo S, et al. Standardisation of the factor H autoantibody assay. Immunobiology 2014; 219:9-16.
8. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002; 30:e57.
9. Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med 2014; 370:632-9.
10. Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F, Dragon-Durey MA, Ngo S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013; 8: 554-62.
11. Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJ. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 2010; 31:E1445-60.
12. Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, et al. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis 2014; 64:633-7.
13. Wehling C, Kirschfink M. Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis. J Thromb Haemost 2014; 12:1437-9.
14. Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 2014; 124: 1715-26.
15. Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S, et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost 2014; 12:1440-8.